Eli Lilly Buys Orna Therapeutics For Next-Gen Cell Therapy

Eli Lilly just made a new bet on the future of medicine, announcing a deal to acquire Orna Therapeutics. The pharma giant said it will acquire Orna for up to $2.4 billion in cash, made up of an upfront payment plus additional payments tied to specified clinical development milestones. The setup they're buying is designed to help patients generate therapeutic agents inside the body, rather than relying on the more complex “take cells out, engineer them, put them back” method used in traditional CAR-T.

Lilly is betting that Orna’s lead program, ORN-252, is the way to go in the new frontier of advanced cell therapies. CD19 is a well-known target in oncology, and established CAR-T products already exist from large pharma peers - but Orna’s “in vivo” delivery could eventually make these therapies simpler to administer and potentially broaden where they can be used. If circular RNA ends up delivering on the promise, Lilly won’t just have acquired a company — it’ll have acquired the right to say, "Yes, we were there for that, too."

This is another example of Lilly using its balance sheet to diversify beyond its blockbuster metabolic franchise and deepen its footprint in genetic medicine and immunology/oncology. The key caveat is timing and risk - Orna’s lead asset is still early, and analysts have flagged that the “in vivo” CAR-T concept remains high-risk and unproven at scale. It also comes with intense competition as other big drugmakers also invest heavily in next-gen cell and genetic therapies. Lilly said it will determine the accounting treatment under GAAP when the deal closes and then reflect it in its reported results and guidance. While the technology is exciting, it’s exactly the sort of gamble that can either be a breakthrough to the future or become a footnote of the past.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726